Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 5:13 pm Sale | 2024-05-21 | 13G | Erasca, Inc. ERAS | ARCH Venture Fund X L.P. | 0 0.000% | -11,055,554 (Position Closed) | Filing History |
| 2023-11-17 4:23 pm Sale | 2023-11-08 | 13G | EQRx, Inc. EQRX | ARCH Venture Fund X L.P. | 0 0.000% | -36,335,375 (Position Closed) | Filing History |
| 2023-02-13 4:08 pm Sale | 2022-12-31 | 13G | Verve Therapeutics, Inc. VERV | ARCH Venture Fund X L.P. | 0 0.000% | -2,508,809 (Position Closed) | Filing History |
| 2023-02-13 4:08 pm Purchase | 2022-12-31 | 13G | Prime Medicine, Inc. PRME | ARCH Venture Fund X L.P. | 12,272,674 12.600% | 12,272,674 (New Position) | Filing History |
| 2022-02-11 4:57 pm Purchase | 2021-12-31 | 13G | EQRx, Inc. EQRX | ARCH Venture Fund X L.P. | 36,335,375 7.500% | 36,335,375 (New Position) | Filing History |
| 2022-02-10 5:04 pm Purchase | 2021-12-31 | 13G | Erasca, Inc. ERAS | ARCH Venture Fund X L.P. | 11,055,554 9.100% | 11,055,554 (New Position) | Filing History |
| 2022-02-09 1:26 pm Purchase | 2021-12-31 | 13G | Verve Therapeutics, Inc. VERV | ARCH Venture Fund X L.P. | 2,508,809 5.200% | 2,508,809 (New Position) | Filing History |